Here is E-GUIDES of Antibiotics, Biodetergents, Stem Cell, etc. ▼
Ligand Pharmaceuticals of La Jolla has licensed DARA to Retrophin, which will use the compounds to explore treatments for kidney disease. The agreement will net Ligand an upfront payment of $1 million and could lead to more than $75 million in milestone payments, and 9-percent in royalties, the company says.
DARA refers to dual-action receptor antagonists, which can help minimize organ damage caused by hypertension.
Sources: Gary Robbins, San Diego Union Tribune
Links to products related:
Allowed tags: <a> link, <b> bold, <i> italics
© 2013 A.G Scientific, Inc. - Privacy Statement